These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36683866)

  • 61. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD.
    Oh S; Tsujimoto T; Kim B; Uchida F; Suzuki H; Iizumi S; Isobe T; Sakae T; Tanaka K; Shoda J
    JHEP Rep; 2021 Jun; 3(3):100253. PubMed ID: 33898958
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Study and Comparison of Metabolic Profile of Lean and Obese Subjects with Non Alcoholic Fatty Liver Disease.
    Shah P; Rathi P; Mandot A; Pal A; Ahire D
    J Assoc Physicians India; 2020 Aug; 68(8):51-54. PubMed ID: 32738842
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.
    Ono H; Atsukawa M; Tsubota A; Arai T; Suzuki K; Higashi T; Kitamura M; Shioda-Koyano K; Kawano T; Yoshida Y; Okubo T; Hayama K; Itokawa N; Kondo C; Nagao M; Iwabu M; Iwakiri K
    JGH Open; 2024 Apr; 8(4):e13057. PubMed ID: 38572327
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017.
    Kim MJ; Lee KJ
    BMC Pediatr; 2020 Mar; 20(1):121. PubMed ID: 32171275
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients.
    Li C; Guo P; Okekunle AP; Ji X; Huang M; Qi J; Jiang Y; Feng R; Li R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):256-262. PubMed ID: 29949199
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes.
    Park H; Jun DW; Park HK; Kim M
    Ann Transl Med; 2020 Dec; 8(23):1583. PubMed ID: 33437782
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.
    Pirgon O; Cekmez F; Bilgin H; Eren E; Dundar B
    Obes Res Clin Pract; 2013; 7(4):e275-83. PubMed ID: 24306155
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.
    Kumar R; Mohan S
    J Clin Transl Hepatol; 2017 Sep; 5(3):216-223. PubMed ID: 28936403
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The natural course of non-alcoholic fatty liver disease.
    Seval GC; Kabacam G; Yakut M; Seven G; Savas B; Elhan A; Cinar K; Idilman R
    Hepatol Forum; 2020 Jan; 1(1):20-24. PubMed ID: 35949661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Higher serum uric acid to HDL-cholesterol ratio is associated with onset of non-alcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels.
    Zhu W; Liang A; Shi P; Yuan S; Zhu Y; Fu J; Zheng T; Wen Z; Wu X
    BMC Gastroenterol; 2022 Apr; 22(1):196. PubMed ID: 35448944
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease: An Analysis of Risk Factors.
    Pattnaik K; Bhuyan P; Singh A; Singh SP; Nath P; Kar S; Misra B; Rath J
    J Clin Exp Hepatol; 2018 Dec; 8(4):367-374. PubMed ID: 30563997
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus.
    Cervo A; Milic J; Mazzola G; Schepis F; Petta S; Krahn T; Lebouche B; Deschenes M; Cascio A; Guaraldi G; Sebastiani G
    Clin Infect Dis; 2020 Dec; 71(10):e694-e701. PubMed ID: 32280969
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.
    Fu CC; Chen MC; Li YM; Liu TT; Wang LY
    Ann Acad Med Singap; 2009 Jan; 38(1):15-7. PubMed ID: 19221666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.